Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
This piece explains glide path withdrawal strategies for index funds, focusing on steady income while managing sequence of returns risk.
25,847 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Internal documents reveal OpenAI posted $21B in losses on $13B in revenue, signaling a costly push to scale AI at bre...
AI is reshaping memory and compute needs, and Micron and AMD sit at the heart of that shift. This guide compares the ...
Tilray Brands is set to report on July 28. This article breaks down whether should tilray brands stock be on your rad...
Timing matters when you claim Social Security. This guide explains the best ages to claim for maximum monthly payouts...
Navitas Semiconductor NVTS reports quarterly results that show revenue growth but ongoing margin pressure. Investors ...
Bitcoin climbs above $71,000, fueling a premarket lift in crypto-linked stocks. Coinbase and Circle lead gains as inv...
Investors wonder whether Intuitive Surgical stock is worth the risk in today’s market. This comprehensive guide weigh...
NVIDIA riding robust AI demand, elevated data-center spending, and resilient margins as 2026 unfolds. Analysts weigh ...
When the market shakes off retail names, patient investors can spot opportunities. Here are two retail growth stocks ...
In April, nebius group stock popped as investors weighed cloud and AI catalysts. This piece breaks down the drivers, ...
Investors debate whether e.l.f. Beauty stock is cheap or fairly valued. This article breaks down growth, margins, and...